Ameriprise Financial Inc Immunic, Inc. Transaction History

Ameriprise Financial Inc

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 14, 2023	SELL	$1.13 - $10.8 $14,373 - $137,376	-12,720 Reduced 44.44%	15,900 $22,000
Q3 2022 Nov 14, 2022	BUY	$3.0 - $5.49 $600 - $1,098	200 Added 0.7%	28,620 $90,000
Q2 2022 Aug 15, 2022	BUY	$3.13 - $12.25 $25,634 - $100,327	8,190 Added 40.48%	28,420 $99,000
Q1 2022 May 16, 2022	BUY	$9.54 - $14.26 $65,826 - $98,394	6,900 Added 51.76%	20,230 $228,000
Q4 2021 Feb 14, 2022	SELL	$7.34 - $10.25 $69,986 - $97,733	-9,535 Reduced 41.7%	13,330 $128,000
Q3 2021 Nov 15, 2021	SELL	$8.05 - $13.29 $6,480 - $10,698	-805 Reduced 3.4%	22,865 $202,000
Q2 2021 Aug 16, 2021	BUY	$11.76 - $16.85 $23,461 - $33,615	1,995 Added 9.2%	23,670 $290,000
Q1 2021 May 17, 2021	SELL	$14.21 - $25.3 $91,867 - $163,564	-6,465 Reduced 22.97%	21,675 $345,000
Q4 2020 Feb 12, 2021	BUY	$14.8 - $20.37 $166,056 - $228,551	11,220 Added 66.31%	28,140 $430,000
Q3 2020 Nov 16, 2020	BUY	$11.74 - $22.0 $198,640 - $372,240	16,920 New	16,920 $314,000

56.3M

100

350K

Ticker IMUX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 30,565,000
Market Cap $30.3M
Description
Immunic, Inc., a clinical-stage biopharmaceutical company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases. Its lead development program is IMU-838, which is in Phase 2 clinical for treatment of relapsing-remitting multiple sclerosis, inflammatory bowel disease, and oth...

Get notified when there are updates to the investment portfolio of Ameriprise Financial Inc, based on Form 13F filings with the SEC.

Stay updated on Ameriprise Financial Inc with notifications on news.